GlassScriptPhysician profile
Andrew B Hilldrup
NPI 1104212323
$11,109.80
in general payments reported to CMS, 2019-2025
55 companies · $2,037 in 2025
The $2,037 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.20 · 2020: $468 · 2021: $2,041 · 2022: $1,914 · 2023: $2,326 · 2024: $2,271 · 2025: $2,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,634.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,751.82 | 2020-2025 | |
| Novo Nordisk INC | $1,076.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,050.78 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $823.34 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $821.39 | 2020-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $769.35 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.58 | 2020-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.44 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $410.67 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $311.96 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $227.44 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $223.95 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $211.57 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $191.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $167.74 | 2020-2025 | Nexletol |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hilldrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.